ClinConnect ClinConnect Logo
Search / Trial NCT06538948

Direct Measurement of Ingestive Behaviour in Relation to Sex Differences and Gastrointestinal Hormone Levels in Patients After Metabolic and Bariatric Surgery

Launched by UNIVERSITY OF ZURICH · Jul 31, 2024

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

Obesity Ingestive Behaviour Bariatric Surgery Gut Hormones Drinkometer

ClinConnect Summary

This clinical trial is studying how bariatric surgery, which helps people lose weight, affects eating and drinking behaviors differently between men and women. The researchers want to learn more about these changes by using a special device called a "drinkometer," which can measure how people drink after surgery. This approach is important because it gives a clearer picture of how surgery impacts eating habits beyond what patients usually report themselves. The goal is to understand better how these changes relate to levels of gut hormones, which play a role in hunger and digestion.

To participate in the trial, you need to be at least 18 years old and have a body mass index (BMI) of 35 or higher if you plan to undergo surgery. If you’re a control participant (not having surgery), you can join if your BMI is 30 or higher or within the normal range (18.5 to 24.9). However, if you have a history of certain health issues, like previous weight loss surgeries or diabetes, you may not be eligible. Throughout the study, participants will provide valuable information that could help improve understanding of how bariatric surgery affects eating behaviors over time.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 year
  • BMI ≥ 35 kg/m2 for patients with planned RYGB or SG operation
  • BMI ≥ 30 kg/m2 for external controls affected by obesity but no planned RYGB or SG within the next 12 months, and
  • BMI ≥ 18.5 kg/m2 and ≤ 24.9 kg/m2 for controls without obesity.
  • Exclusion Criteria:
  • history of previous bariatric operations and/ or revisional surgery (e.g., alteration of limb lengths after primary RYGB),
  • smoking,
  • established diagnosis of type 1 or 2 diabetes mellitus, and
  • polycystic ovary syndrome (PCOS).

About University Of Zurich

The University of Zurich, a leading institution in research and education, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust framework for conducting high-quality research, the university collaborates with multidisciplinary teams of experts to explore cutting-edge therapeutic approaches and interventions. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the utmost integrity, aiming to contribute valuable insights to the medical community and enhance health outcomes globally.

Locations

Männedorf, Zurich, Switzerland

Zurich, , Switzerland

Patients applied

0 patients applied

Trial Officials

Marco Bueter, MD, DPhil

Principal Investigator

University of Zurich

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported